e-Pharmatimes

Wegovy® (semaglutide 2.4 mg) Shows Liver Health Benefits in MASH Beyond Weight Loss Wegovy® (semaglutide 2.4 mg) Associated with Liver Health Benefits in MASH — Not Entirely Explained by Weight Loss Published: November 2025 | Category: Pharma & Hepatology Executive summary: A new post hoc analysis of the ESSENCE phase 3 program indicates that weekly semaglutide 2.4 mg (Wegovy®) was associated with improvements in liver inflammation, steatosis and fibrosis-related outcomes in adults with metabolic dysfunction–associated steatohepatitis (MASH) and liver scarring. Notably, a mediation analysis suggests these liver benefits are not explained solely by the magnitude of weight loss, implying potential weight-independent effects of semaglutide on liver health. [1][2] Key findings Semaglutide 2.4 mg recipients experienced greater improvement in liver injury (steatohepatitis) and liver-related non-invasive tests c...

Weight Loss Drugs and the Indian Pharmaceutical Economy: A New Era of Health and Business 💊 The New Revolution in Weight Loss: Beyond Diets and Gyms Weight management is no longer limited to gym routines and calorie counting. India’s healthcare landscape is witnessing a scientific revolution driven by advanced weight loss drugs such as semaglutide (Wegovy) and tirzepatide (Mounjaro) . These modern therapies are reshaping the country’s pharmaceutical economy, creating new business opportunities for both global and Indian companies. 🇮🇳 India’s Weight Loss Drug Boom in 2025 According to Reuters , India’s weight loss drug market crossed ₹600 crore in mid-2025 — a growth rate few other pharma categories can match. Global giants like Eli Lilly (Mounjaro) and Novo Nordisk (Wegovy) are driving the wave, while Indian companies such as Dr. Reddy’s, Lupin, Zydus, and Sun Pharma are fast-tracking their own anti-obesity formulations. For perspective, Mounjaro was launched ...

Koselugo (Selumetinib) Approved in the EU for Plexiform Neurofibromas in Adults with Neurofibromatosis Type 1 Published on: November 2025 | By: ePharma Times AstraZeneca and Merck & Co., Inc. have announced that Koselugo (selumetinib) has been granted marketing authorization in the European Union for the treatment of adults with Neurofibromatosis Type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PNs). Why This Matters NF1 is a rare genetic condition affecting around 1 in 3,000 people worldwide. These tumors can cause pain, disfigurement, and neurological complications. This EU approval marks a critical advancement in targeted therapy options for NF1, expanding treatment accessibility for adult patients across Europe. Clinical and Patient Impact Clinical studies demonstrated that selumetinib led to meaningful tumor shrinkage and improved patient outcomes. By targeting the MEK pathway , Koselugo re...

AI in Healthcare & Pharma: How Artificial Intelligence Is Transforming Drug Discovery and Medical Devices Artificial Intelligence (AI) is reshaping the global healthcare ecosystem. From drug discovery to diagnostics and patient care, AI has become the driving force behind the next wave of innovation in the pharmaceutical and medical device sectors. This article explores how AI technologies are transforming every stage of the healthcare value chain. AI in Pharmaceutical Development Accelerating Drug Discovery AI algorithms now analyze massive biological and chemical datasets to identify potential drug candidates in record time. Machine learning models predict molecular properties, toxicity levels, and drug–target interactions — drastically reducing preclinical failure rates. Major pharma companies are partnering with AI startups to shorten drug discovery timelines by up to 50%. Optimizing Clinical Trials AI supports patient selection, risk prediction, and real-time tr...

Novo Nordisk has stood up on the side of Victoza after persuasive US buyer bunch Public Resident required the diabetes medication to be removed. Public Resident has asked the US Food and Medication Organization to quickly eliminate Victoza (liraglutide) from the market "since it puts patients at higher gamble of thyroid disease, pancreatitis, serious hypersensitive responses and kidney disappointment that offset any recorded clinical advantage". The backing bunch guarantees that the once-everyday human glucagon-like peptide-1 (GLP-1) simple "is the main medication endorsed by the FDA or in the endorsement pipeline that causes thyroid C-cell growths in the two genders of rodents and mice, doing as such at drug openings like those found in individuals taking the suggested portion - a striking admonition sign". Additionally, in the initial 17 months of Victoza being available, 200 patients were determined to have intense pancreatitis, as per Public Resident's audit...

Quality treatment includes grown-ups with hemophilia B and carries restored desire to patients across Europe CSL has declared that the European Meds Organization's (EMA) Panel for Restorative Items for Human Use (CHMP) has taken on a positive assessment of etranacogene dezaparvovec. It concerns the restrictive showcasing authorisation (CMA) of the treatment, which decreases the pace of yearly drains with a solitary mixture, among grown-ups with hemophilia B. Assuming that the showcasing authorisation is effectively endorsed by the European Commission (EC) - under the brand name HEMGENIX - it would turn into the principal quality treatment for individuals living with hemophilia B in the EU and European Monetary Region. A positive CHMP assessment followed discoveries from the Expectation B preliminary, the biggest quality treatment preliminary in hemophilia B to date. These discoveries exhibited that hemophilia B patients, when treated with etranacogene dezaparvovec, showed stable ex...